Showing posts with label HIV. Show all posts
Showing posts with label HIV. Show all posts

Saturday, April 14, 2018

JIAS - Special Issue: Towards global viral hepatitis elimination for all patients in all income settings

Journal of the International AIDS Society
Published on behalf of the International AIDS Society

Special Issue: Towards global viral hepatitis elimination for all patients in all income settings
Guest Editors: Marina B Klein, Karine Lacombe

The complete supplement file is available at

First Published: 10 April 2018
Full text

Open Access
How far are we from viral hepatitis elimination service coverage targets?

Yvan J‐F Hutin Marc Bulterys Gottfried O Hirnschall e25050
First Published: 10 April 2018
Full text

Research Articles
Open Access
Hep‐CORE: a cross‐sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017

Jeffrey V Lazarus Samya R Stumo Magdalena Harris Greet Hendrickx Kristina L Hetherington
Mojca Maticic Marie Jauffret‐Roustide Joan Tallada Kaarlo Simojoki Tatjana Reic Kelly Safreed‐Harmon the Hep‐CORE Study Group e25052
First Published: 10 April 2018
Full text

Open Access
Approaches for simplified HCV diagnostic algorithms

Slim Fourati Jordan J Feld Stéphane Chevaliez Niklas Luhmann e25058
First Published: 10 April 2018
Full text

Open Access
Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

Rachel Sacks‐Davis Joseph S Doyle Andri Rauch Charles Beguelin Alisa E Pedrana Gail V Matthews Maria Prins Marc van der Valk Marina B Klein Sahar Saeed Karine Lacombe
Nikoloz Chkhartishvili Frederick L Altice Margaret E Hellard e25051
First Published: 10 April 2018
Full text

Open Access
Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low‐ to high‐income settings: making sure no one is left behind

Céline Grillon Priti R Krishtel Othoman Mellouk Anton Basenko James Freeman Luís Mendão
Isabelle Andrieux‐Meyer Sébastien Morin e25060
First Published: 10 April 2018
Full text

Open Access
Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?

Natasha K Martin Anne Boerekamps Andrew M Hill Bart J A Rijnders e25062
First Published: 10 April 2018
Full text

Open Access
Research gaps in viral hepatitis

Anders Boyd Léa Duchesne Karine Lacombe e25054
First Published: 10 April 2018
Full text

Friday, April 6, 2018

TAGline Spring 2018: Activism and the elimination of HIV, HCV, and TB

TAGline Spring 2018: Bend the curves

Bend the curves: Activism and the elimination of HIV, HCV, and TB
Incremental change—activism that successfully defends or advances critical research or policy—can sometimes feel inconsequential, particularly when it is hard won, resource intensive, and intangible. But in the context of public health strategies with ambitious targets and formidable stakeholder engagement, it is an undeniable facet of progress. In this issue of TAGline, Treatment Action Group (TAG) highlights some important recent successes and challenges in meeting its overarching goals: moving beyond achingly slow trends and sharply bending the curves on new HIV, hepatitis C, and TB infections, suffering, and deaths.

Spring TAGline contains:
Bend the Curves:
Activism and the Elimination of HIV, HCV, and TB

By Tim Horn
The Usual Suspects:
Common Challenges for ETE Planning and Implementation in Emerging Jurisdictions

By Jeremiah Johnson
New York State EtE Campaign Update:
Successes & Challenges

By Jeremiah Johnson
The Role of Vaccines and Cures in HIV Elimination
By Richard Jefferys
It’s up to You, New York:
Moving towards HCV Elimination in the Empire State
By Annette Gaudino
Global HCV Elimination Targets and Challenges:
An Interview with Andrew Hill

By Bryn Gay & Annette Gaudino
From Moscow to New York and Beyond:
The Future of Tuberculosis Research and Development

By Safiqa Khimani and Mark Harrington
The United Nations’ Back Yard:
TB Elimination in New York State and the U.S.

By Erica Lessem
In a State of Disunion:
HIV, TB, and HCV Elimination Policies and Priorities Under the Trump Administration

By Suraj Madoori

TAGline Spring 2018

Other Updates @ TAG
Now Available in Spanish: Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV
April 4, 2018 – You can now download a Spanish version of our Training Manual for Treatment Activists: Hepatitis C and HIV Coinfection!

Saturday, March 17, 2018

March HCV Newsletters & America’s Opioid Crisis: Overdoses Still Increasing

March HCV Newsletters & Updates: America’s opioid crisis is still increasing

In March the CDC reported emergency department visits for opioid overdoses rose 30% across the US.

- Particularly hard hit were Midwestern states, with a 70% increase in opioid overdoses. 
- Opioid overdoses increased for both sexes and all age groups. 
- People who have had an opioid overdose are more likely to have another.  
- Repeat opioid overdoses can be avoided through treatment referrals provided during emergency department visits.  
- Timely and coordinated response efforts can also better prevent more opioid overdoses in the community. 
- Learn more about preventing opioid overdoses and what to do if an overdose occurs in order to save a life. 

For more information, visit

In The Media
America’s opioid crisis has become an “epidemic of epidemics”
By Ella Nilsen Mar 6, 2018
Opioid and heroin use is causing a dramatic spike in new hepatitis C infections, as well as dangerous bacterial infections that, if left untreated, can cause strokes and require multiple open-heart surgeries. Doctors and public health officials also fear America is on the brink of more HIV outbreaks, driven by intravenous drug use.

Jump In Overdoses Shows Opioid Epidemic Has Worsened
Rob Stein
In just one year, overdoses from opioids jumped by about 30 percent, according to the a report released Tuesday by the Centers for Disease Control and Prevention.

"Overall as a nation, we are still failing to adequately respond to the opioid addiction epidemic," says Dr. Andrew Kolodny, co-director of opioid policy research at Brandeis University. "It is concerning that 20 years into this epidemic, it is still getting worse. The number of Americans experiencing opioid overdoses is still increasing."

Check out this months newsletters & blog updates with information and support for people living with or treating viral hepatitis.

Read today's news or a nice summary of notable headlines published in the latest issue of The Weekly Bull.

HCV Advocate
HealthWise – Is Hepatitis C Treatment Safe?
By Lucinda Porter, RN – My first article for the HCV Advocate appeared 20 years ago. Hepatitis C virus infection (HCV) wasn’t curable yet. HCV is now easily curable and one would think the problem is solved, but it isn’t. Numerous obstacles stand in the way of eliminating this disease. A large percentage of the population is still undiagnosed because of inadequate HCV screening. Access to health care is uneven, particularly for those who need it the most.”

Review and Editorial Comments by Alan Franciscus Executive Director of the Hepatitis C Support Project, Editor-in-Chief of the HCV Advocate Website

List Of Articles
1- Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease—L.I. Backus, et. al.

2- Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse—A S Barritt, et. al.

3- Population-level outcomes and cost-effectiveness of expanding the recommendation for age-based hepatitis C testing in the United States—J. A. Barocas, et. al.

4- Glecaprevir/Pibrentasvir for Hepatitis C Virus Genotype 3 Patients with Cirrhosis and/or Prior Treatment Experience: A Partially Randomized Phase 3 Clinical Trial—D. Wyles, et. al.
National Viral Hepatitis Roundtable
NVHR Newsletter
NVHR Welcomes Two Federal Actions to Help Prevent and Treat Hepatitis B
America Liver Foundation 
The New York City Hepatitis C Task Force
British Liver Trust
HEPVOICE - World Hepatitis Alliance
GI & Hepatology
From the AGA Journals
Sofosbuvir/ledipasvir looks good in HBV coinfected patients
Hep Magazine
Advocacy in Action
Best of You
Is U.S. Lagging in Hepatitis Efforts?
As Injection Drug Use Rises, So Does Hep C
An Early Cure Protects the Liver?
Cured of Hep C, at Risk of Fatty Liver

Blog Updates
Hep Blogs
Factors That May Increase Your Risk of Death from Hepatitis C
March 5, 2018
By Lucinda K. Porter, RN
Barely a week goes by in which I don’t read about the increased risk of death from hepatitis C. People living with this virus are at risk of dying prematurely from all the major causes of mortality, such as cancer, heart disease, and stroke. However, it appears that certain behaviors may hasten death when you have hepatitis C.
By Kimberly Morgan Bossley - March 5, 2018
I had a very unsettling experience a few years back that really got me to thinking about how knowledgeable are most physicians about hep C. Finding a the Right Doctor for You...

5 Things That Make Stress Worse 
By Karen Hoyt - March 2, 2018
Stress can make you miserable. Everything sets you on edge. The noise someone makes when they eat. The bank teller wanting copies of whatever when you’re rushed. Your neighbor mowing his lawn...

Effects of Chronic Illness on Our Moods 
By Daryl Luster - March 1, 2018
Sounds like depression by another name, but is it necessarily as simple as that? I am not suggesting that depression is simple or should ever be dismissed as “nothing” as some might...
Blogs - Healio
BLOG: A word of caution to insulin pump users to ‘spring forward’
It’s happening again — the daylight saving time spring ritual. This year the daylight saving time change will...
BMC Blog
Raquel Peck 1 Mar 2018
On Zero Discrimination Day (March 1st), the World Hepatitis Alliance (WHA) is encouraging the hepatitis community to challenge misconceptions and speak out about the devastating impact of stigma and discrimination across the globe.

Xu Zhang 5 Mar 2018
Pain, an unpleasant feeling and physical and psychological burden for patients, has drawn the attention of dedicated scientists trying to tackle the problem from… 
Oxford University

Romance and reality: clinical science in liver transplant for alcoholism
By Thomas P. Beresford 4 Mar 2018
The alcoholic with liver disease has a liver from birth that is genetically vulnerable in some way to the ravages of drink. Only about 15% of heavy drinkers develop alcoholic liver disease. The other 85% of heavy drinkers will never need a transplanted liver. Should the 15% die because of their genetic vulnerability to alcoholism—a treatable condition in which large numbers recover every year?
The internet is an amazing source of information and misinformation. How do you know if what you are reading is accurate?

Healthy You

Medical News Today
Last updated Fri 2 March 2018
By Tim Newman Reviewed by Elaine K. Luo, MD
This MNT Knowledge Center article will cover the main roles of the liver, how the liver regenerates, what happens when the liver does not function correctly, and how to keep the liver healthy.
The Atlantic
Evolution doomed us to have vital organs fail. For years, experts failed us, too.
Harvard Health Blog
In November 2017 the American Heart Association and the American College of Cardiology changed the definition for high blood pressure. One day your blood pressure of 130/80 was normal — the next day you had stage 1 hypertension, and suddenly you found yourself in a higher risk category formerly reserved for people with blood pressure of 140/90. While you probably don’t feel like celebrating the change, it may actually be a good thing.

Conference on Retroviruses and Opportunistic Infections CROI 2018
News, slidesets, interviews, and webinars

Thanks for stopping by.

TGIF Rewind: HCV and HCC, Tips For Kidney Health & Treating HCV According to Genotype

Its Friday! Do you have any plans for this weekend? Thinking I may go play with the grandkids pup, she's so cute! In any event here are a few updates on the topic of viral hepatitis.

Starting over at Healio, the March issue of HCV NEXT is out, with a feature on HCV treatment for people who inject drugs, the associated stigma, and critical need for awareness. Bloggers from around the web have been busy as well, Karen Hoyt is your resource for everything HCV, read her new article about kidney disease, filled with helpful tips; from labs to nutrition. Greg Jefferys writes about treatment options for each HCV genotype, his article is easy to understand, a must read, available online at Hep Blogs. Finally, a link is provided below to the following journal updates; Fatty liver disease & HCV (in case you missed it), and two articles on treatment for patients with HCV and HCC.

In The Journals
World J Gastroenterol. Mar 21, 2018; 24(11): 1269-1277
Published online Mar 21, 2018. doi: 10.3748/wjg.v24.i11.1269
Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals
This is the first prospective study to assess the prevalence of fatty liver in hepatitis C patients who have achieved a sustained virological response with direct-acting antivirals. The study’s findings that fatty liver is present in 47.5% of these patients and that some steatotic patients have clinically significant fibrosis despite normal liver enzymes should raise awareness of the post-sustained virological response (SVR) prevalence of fatty liver and the importance of post-SVR assessment of steatosis and fibrosis and long-term follow up with these patients.
Full text

On Twitter
The following full-text articles were downloaded and shared by Henry E. Chang via twitter.
Emerging data are demonstrating lower sustained virologic response (SVR) rates in patients with HCC compared with patients without HCC. Conflicting studies have also suggested that rates of HCC recurrence in patients with a history of HCC can potentially be increased or decreased on DAA therapy. This review will provide a brief overview of these data and inform practitioners on important considerations to make when prescribing DAA therapy for patients with HCV and HCC

Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN & cirrhosis regression 
The finding that HCC developed also in SVR patients with cirrhosis regression (F3)greatly attenuates the need for refining the management of SVR patients in relation to residual liver fibrosis. The fact that regressed patients developed HCC later than non regressors deserves attention.....

March Updates On This Blog
Stagnation of fibrosis regression is associated with a high risk for HCC after SVR
Side effects associated with different hepatitis C direct-acting antiviral drugs
Dos and Don’ts in the Management of Cirrhosis: A View from the 21st Century
Higher levels of vitamin D is associated with a lower risk of liver cancer
March 2018 - Recruiting hepatitis C clinical trials

The following articles appeared in the March print edition of HCV NEXT, provided online at Healio.
Moving Beyond the Low-Hanging Fruit in HCV Diagnosis and Treatment
HCV Next, March/April 2018
The trouble in engaging difficult to reach populations is, well, that they are difficult to reach. The low-hanging fruit of diagnosing and treating people who have…

Treating People Who Inject Drugs:
HCV Next, March/April 2018
As a population, people who inject drugs have the highest prevalence and incidence of hepatitis C infection. Despite this, people who inject drugs have historically had…

Blog Updates
I Help C - Your Best Friends Guide to Hep
Karen Hoyt March 10, 2018
If you are going to drown your Hepatitis C or cirrhosis sorrows – do it with water. Kidney disease is not as silent as liver disease, but it sure will sneak up on you if you’re not taking precautions. If you were holding your breath out of fear, you can let it out now. Your kidneys do NOT get damaged quite like the liver if you take care of your kidneys. This post celebrates with Wisdom for World Kidney Day.

Hep Blogs
Hepatitis C Treatment Options
By Greg Jefferys
An explanation of the various hepatitis C treatment options for each genotype. 

Check out a new patient friendly video launched by Hepatitis C activist Greg Jefferys, with a look at current therapies used to treat the hepatitis C virus across all HCV genotypes.

On March 8, 2018, NVHR participated HHS’s webinar, Hidden Casualties: National Partners’ Response to the Opioid Epidemic and Infectious Diseases. Below is a transcript of NVHR’s portion of the webinar.

Creating a World Free of Hepatitis C
Who’s in Charge, You or Stress?
Lucinda Porter March 15, 2018 All of us have stress. Life is an unpredictable string of events, and sometimes it feels like a circus juggling act. Lily Tomlin said, “Reality is the leading cause of stress for those in touch with it.”

Scratching That Itch
By Kimberly Morgan Bossley - March 15, 2018
Scratching that itch that seems to never go away. You know the one that interrupts your daily activities and your sleep. Itchy and irritated This has always been a big issue with...

Does Hepatitis C Go Away On Its Own?
By Carleen McGuffey - March 14, 2018
Hepatitis C can go away spontaneously in approximately 20% of cases, but the majority of the time, hep C becomes a chronic infection.1 Its a very hardy virus. If you have ever...

Hepatitis C and Opioid Addictions
By Karen Hoyt - March 13, 2018
If you are under 40 and diagnosed with Hepatitis C, you probably have more problems than you know what to do with. If you got HCV through a dirty needle, there is...
The real cause of the opioid epidemic: the government
Rudolph, MD March 13, 2018
The patient The patient is a forty-two-year-old male who works in the auto manufacturing arena. He takes one step to his left, he turns and lifts a seventy-five-pound piece of metal from a moving conveyor belt. He turns back and takes one step to his right to put the metal on his table. He tightens three screws, lifts the metal off the table to take one step to his right, turning, ...

Harvard Health Blog
Monique Tello, MD, MPH March 16, 2018
A recently published clinical guideline on vitamin and mineral supplements reinforces every other evidence-based guideline, research review, and consensus statement on this topic. The bottom line is that there is absolutely no substitute for a well-balanced diet, which is the ideal source of the vitamins and minerals we need.

Hep B Blog
What to do about hepatitis B when you’re pregnant?
March 14, 2018 Around the world, the most common mode of hepatitis B transmission is from mother to child. Unfortunately, pregnant mothers who have hepatitis B can transmit the virus to their newborn during the delivery process. 90% of these HBV infected babies will progress to chronic infection putting them at increased risk of serious liver disease or liver cancer later in life.
March 7, 2018
Discrimination is unethical, unnecessary and a violation of human rights. Hepatitis B is simply not transmitted through casual contact. The stigma that persists is based on ignorance and it impacts millions around the world daily.

BMJ Opinion
Richard Lehman’s journal reviews—12 March 2018
March 12, 2018
Fatty liver: the untapped market
Nearly a third of men in the richest countries have fatty livers: women and middle-income countries are racing to catch up. How about that for a market? An unlucky few of these will develop fibrosis and of these an unlucky few will die of liver failure or hepatocellular carcinoma. So you have your advertising copy sorted too. But by the same token any drug given to such a vast number of people will have to be very safe and will need some very lengthy hard-end point trials. And there is an excellent cheap candidate drug already—pioglitazone, which can reverse cirrhosis as well as steatosis. But never mind all that. Let’s read about a 116-patient phase 2 trial of an injectable experimental drug, lasting 12 weeks. In that time, a third of the participants experienced diarrhoea and three-quarters lost more than 5% of their liver fat. “Larger clinical trials of longer duration are now needed to fully assess the safety and efficacy of NGM282.” Might The Lancet not have found better use for its space in the meantime?

ACP Internist Blog
Scoping out the reasons for overuse of colonoscopy
Michael Kirsch, MD, FACP
In our practice we have an open endoscopy system, as do most gastroenterologists. This means that other physicians or patients themselves can schedule a procedure with us without seeing us in advance for a consultation. Of course, we are always pleased to see any of these patients for an office visit in advance, but many patients prefer the convenience of accomplishing the mission in one stop. This is reasonable for patients who truly need our technical skill more than our medical advice.

Enjoy the upcoming weekend. 

Saturday, March 10, 2018

The Global HIV Epidemic - What Will It Take to Get to the Finish Line?

March 6, 2018

What Will It Take to Get to the Finish Line?
Ingrid T. Katz, MD, MHS1,2,3; Peter Ehrenkranz, MD, MPH4; Wafaa El-Sadr, MD, MPH, MPA5,6

JAMA. Published online March 6, 2018. doi:10.1001/jama.2018.2093

Recent estimates indicate that approximately 57% of the 36.7 million people living with HIV worldwide are in care and receiving antiretroviral treatment (ART).1 Although this represents a 20-fold increase in less than 2 decades in the number of people receiving ART, these findings also demonstrate that the global community is still far from achieving the targets laid out by the Joint United Nations Programme on HIV/AIDS (UNAIDS) called 90-90-90—specifically, 90% of all people living with HIV knowing their status; 90% of those diagnosed receiving sustained ART; and 90% of those receiving ART achieving viral suppression by 2020. Accomplishing this ambitious agenda requires sustainable approaches in countries with the highest burden of HIV.2

Monday, March 5, 2018

Meeting Coverage - Conference on Retroviruses and Opportunistic Infections CROI 2018

Conference on Retroviruses and Opportunistic Infections (CROI)
March 4 to March 7, 2018
Boston MA

HIV and ID Observations.
Paul Sax is Clinical Director of the HIV Program and Division of Infectious Diseases at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School.
Paul E. Sax, MD
March 11th, 2018
Really Rapid Review — CROI 2018, Boston
CROI clearly remains our best meeting, the only one that brings together so much high quality research from so many disciplines. Clinical, basic, and behavioral researchers all have a place here.
National AIDS Treatment Advocacy Project NATAP
Coverage @ NATAP
Jules Levin, Executive Director
Our web site is read all over the world and is recognized as a leading reliable source of HIV and Hepatitis treatment information for doctors, patients, and others. The information on the site is scientifically oriented, abundant, and comprehensive in its coverage of both HIV and Hepatitis. The site is regularly updated with new articles, studies and highlights from various major conferences.

Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018
Begin here.....
Coverage @  Healio
Healio brings you the highlights from the Conference on Retroviruses and Opportunistic Infections (CROI). Refer back to this page often for the latest news from CROI, perspectives and interviews with leading researchers and clinicians, and to review archives of past meetings.

CROI chair: HIV conference promises to be ‘exciting meeting’
March 4, 2018
BOSTON — CROI 2018 Chair Judith S. Currier, MD, professor of medicine and division chief of infectious diseases at…
Begin here....
Coverage @ NAM aidsmap
We will be reporting on key research presented at the conference, publishing news online and sending out four conference news summary bulletins – three during the week of the conference and one the week after. The bulletins will be available in English, French, Spanish, Portuguese, Italian and Russian. You can sign up here to receive these email bulletins. (If you already receive NAM’s regular email bulletins, you will automatically receive our conference bulletins.)

Experimental antibody plus TLR7 agonist maintains viral suppression in monkeys
Liz Highleyman
Published: 05 March 2018
Treatment with a broadly neutralising antibody plus an immune-stimulating drug led to long-term viral remission after interrupting antiretroviral therapy in a monkey study, according to data presented at the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) this week in Boston.
Begin here...
Coverage @ Contagion
Contagion® will be providing exclusive coverage on the conference, and so, keep your eyes peeled for session coverage and interviews with some of the key presenters.

Harnessing the Power of International, Interdisciplinary Collaboration on the Quest to Cure HIV
International interdisciplinary collaboration will bring us that much closer to a cure for HIV.
MedPage Today
Coverage @ MedPage Today
MedPage Today, a CE and CME accredited medical news service, provides free continuing education to healthcare professionals in addition to the latest news.

Sex in Late-Stage Pregnancy Tied to Higher HIV Risk Biological changes may increase HIV transmission in serodiscordant couples 
BOSTON -- The risk of HIV transmission per sex act increased steadily through pregnancy, and was highest during postpartum, researchers reported here. In two HIV prevent studies that included 2,571 African women living in HIV serodiscordant relationships (female partners did not have HIV), the risk of HIV infection was 2.97-fold higher during the second two trimesters of pregnancy (P=0.01) and 4.18-fold higher during the 6-month post partum period (P=0.01), according to Renee Heffron, PhD, of the University of Washington in Seattle, and colleagues.
Begin here....
Clinical Care Options HIV
Coverage @ Clinical Care Options
Get up to date on the latest HIV data with rapid Capsule Summaries, downloadable slidesets, and live, expert-led Webinars covering key studies from Boston.

New Data from CROI 2018
Expert faculty members summarize key studies from this important annual conference.
Expert Review @ ViralEd
ViralEd, Inc. is a physician-directed medical education company whose mission is to provide thought-provoking, effective, and evidence-based CME to help improve health care provider knowledge and professional development. For over a decade, ViralEd's team of dedicated professionals have specialized in using a blended learning approach that combines innovative technology with live programming to provide programs and medical education content that is unique, timely, and of high quality.

The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018). This program consists of three components: (1) CME Internet Symposium: CROI 2018 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) Rapid-Fire Review of CROI 2018: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (3) From Conference to Clinic: Reviewing and Applying Data From CROI 2018: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

The CME Internet Symposium: CROI 2018 Expert Review will feature a panel of HIV experts reviewing and discussing key presentations on antiretroviral therapy presented at CROI 2018. The review and discussion will focus on HIV therapeutic options and developments, including: current treatment and management strategies, algorithms and recommendations, therapies in development, epidemiology, and diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All online components of the program can be accessed at

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at CROI 2018 and it is not sanctioned by the organizers of CROI 2018.

Wednesday, February 28, 2018

Journal, and patient blog updates - Beyond one virus: vaccination against hepatitis B after hepatitis C treatment.

Read the latest journal and viral hepatitis updates from patient bloggers who work hard to educate and inspire us all.

HCV Advocate
HCV Advocate has just published their Monthly Newsletter, check out the latest "March issue."

Judy Stone
Given the experience in Indiana, which saw a spike in STDs, Hepatitis C and HIV, Walensky expects the HIV/Hepatitis C to “go up in lock-step with those” other sexually transmitted diseases. Walensky raised interesting points regarding HIV medications as well, noting “In the past 2-3 years, the cost of first line antiretroviral ...

Gilead Sciences Canada, Inc. (Gilead Canada) today recognizes the Ontario Ministry of Health and Long-Term Care for its leadership in the expansion of access to therapies that treat chronic hepatitis C virus infection under the Ontario Drug Benefit (ODB) Program. Today, all eligible ODB recipients will have greater access to treatment, regardless of the severity of disease (fibrosis level), to achieve a cure and improve their quality of life. Patients with chronic hepatitis C will no longer have to wait for their disease to progress before starting treatment.

Specialty Pharmacy Times
A study published by Clinical Infectious Diseases suggests that screening all adults for HCV may be cost-effective and could also identify more patients with the infection than current recommendations.

In The Journals
Volume 18, No. 3, p246–247, March 2018
New treatments for hepatitis C virus (HCV) infection with direct-acting antivirals provide an extraordinary cure rate. A recent Article by Xavier Forns and colleagues1 shows an outstanding 99% sustained virological response among all viral genotypes.

Developing a universal influenza vaccine — a vaccine that can provide durable protection for all age groups against multiple influenza strains, including those that might cause a pandemic — is a priority for the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. Writing in the Journal of Infectious Diseases, NIAID officials detail the Institute’s new strategic plan for addressing the research areas essential to creating a safe and effective universal influenza vaccine. They describe the scientific goals that will be supported to advance influenza vaccine development. The strategic plan builds upon a workshop NIAID convened in June 2017 that gathered scientists from academia, industry and government who developed criteria for defining a universal influenza vaccine, identified knowledge gaps, and delineated research strategies for addressing those gaps.

Journal Of Hepatology
«The times they are a’changin’» – Positioning the European Association for the Study of the Liver in the changing landscape of hepatology
Bob Dylan’s words hold relevance for several forces currently acting upon hepatology and the European Association for the Study of the Liver (EASL). The arrival of direct-acting antivirals, which marked the definitive transformation of hepatitis C virus infection into a curable disease with a new focus on public health represents only one of the changes. Fuelled by demographic changes of an ageing population, by migration movements in and beyond Europe, as well as by lifestyle changes and the explosion of the metabolic syndrome, other areas are in rapid expansion. The most pronounced of which are related to non-alcoholic fatty liver disease (NAFLD), hepatitis B virus infection, alcoholic disease and hepatocellular carcinoma (HCC). Moreover, tremendous dynamics in science and drug development now offer treatment options for patients with rare diseases that are also increasing in prevalence. Major trends at the societal level also have an impact on EASL.

Foster GR, et al. Hepatol. 2018;doi:10.1002/hep.29852.
February 27, 2018
Zepatier demonstrated high efficacy among patients with hepatitis C genotype 3, regardless of treatment experience or baseline resistance-associated substitutions, according to recently published data.

Healio Gastroenterology
Ira M. Jacobson, MD
The field of hepatology has seen revolutionary changes occuring within hepatitis C therapy over the past few years. This extraordinary newfound ability to cure almost all patients with chronic HCV raises many questions about clinical outcomes.

“Herbal and dietary supplement-induced liver injury is an increasing healthcare problem,” Lucena said. “The present study is a comprehensive analysis of all HILI cases reported to the Spanish DILI Registry to date. This study provides relevant information about clinical features associated with HILI, and highlights the importance of identifying all medicinal products, prescription drugs as well as herbal and dietary supplement products, taken by patients who develop liver abnormalities.”

Of Interest @ Healio
By some estimates, there are between 50,000 and 200,000 apps intended to serve a medical need. These apps claim to manage symptoms of depression, improve care in patients with irritable bowel disease, manage diabetes as well as help patients with a myriad of other medical uses.

Read today's news or a nice summary of notable headlines published in the latest issue of "The Weekly Bull."

Hepatitis B
AGA Blog
Gastroenterology and Clinical Gastroenterology and Hepatology.
Dr. Kristine Novak
NVR3–778, a capsid assembly modulator, reduces serum levels of hepatitis B virus (HBV) DNA and HBV RNA in mice with humanized livers and stable HBV infection, researchers report in the February issue of Gastroenterology. The combination of NVR3–778 and interferon prevented viral replication and HBV RNA particle production to a greater extent than....

Hep B Blog
Hepatitis B Foundation
February 28, 2018
Welcome to “Journey to the Cure” This is a web series that chronicles the progress at the Hepatitis B Foundation and Baruch S. Blumberg Institute towards finding the cure for hepatitis B.

Hepatitis C
In a recent publication in Clinical Infectious Diseases, CHERISH trainee Dr. Shashi Kapadia, CHERISH staff member Philip Jeng, CHERISH director Dr. Bruce Schackman and CHERISH research affiliate Dr. Yuhua Bao characterize variation in DAA utilization among states and explore the association between changes in Medicaid treatment eligibility criteria and trends in DAA utilization.

Life Beyond Hep C
Connie M. Welch
Hep C Patient John, shares his conquering story from hepatitis C, end stage liver disease, liver cancer and liver transplant. Connie: John, Thank you for being with us this week and sharing your awesome story of how you’ve come through this battle with liver disease.

Hep Blogs
By Connie M. Welch 
February 28, 2018 
The guiding principle of the national transplant system has been; locals first. Most organs stay in the areas where they are donated, even if sicker patients are waiting in other parts of the country.

Hep - Forums 
Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.
By Kimberly Morgan Bossley
February 27, 2018
Working has always been my “thing” you can say. I started very young and have never not had a job or career. During the Spring of 2005, I was running three individual companies. All...

By Daryl Luster
February 26, 2018
Yes I know, a sensational title. I apologize for the dramatic tone. The thing is that we are inclined to do this bracing thing in preparation for storms, difficult events, or things...

By Kimberly Morgan Bossley
February 23, 2018
Stop complaining about your situation and start doing things to change it. How many times have we all heard this through our journey in life? I know for myself growing up it... - Forums
Talk about it - privately
Have questions? Want to talk about Hep C? Connect with others privately in our forums!

Nature Blogs
Amy Maxmen
Several vaccines and drugs for preventing the spread of HIV are showing signs of success in clinical trials, three decades after scientists began the search. But some researchers fear that progress will stall without a coordinated strategy to ensure that the most promising therapies to prevent infection win support from policymakers and reach the people who need them.

The new edition of "HIV update is now online."
Untreated hepatitis C can cause serious liver disease, including fibrosis (a build-up of fibrous scar tissue, leading to a ‘stiff’ liver) and cirrhosis (serious scarring that blocks blood flow through the liver, kills liver cells and interferes with liver function). The more advanced the fibrosis and cirrhosis, the greater the risk of serious illness and death. Successful hepatitis C treatment can clear the virus from the body. But less is known about its long-term impact on fibrosis or cirrhosis.

Women and Viral Hepatitis
A systematic review and meta-analysis revealed that maternal viral load among mothers with hepatitis B was a significant risk factor for mother-to-child transmission, and was dose-dependent with HBV transmission incidence.

Rates of hepatitis C infections are on the rise among adults in the United States, and some of those adults are pregnant women.

Healthy You
Stanford Medicine 
February 26, 2018
There's a wide debate surrounding the use of antidepressants. Do they really work? If so, how well? And how do you know which one to select?

Harvard Health
Christopher Bullock, MD, Carolyn A. Bernstein, MD, FAHS
Getting regular exercise is one of the best actions you can take to improve or maintain your overall health. Fitting exercise into your life is not as difficult as it might seem, but it does require some planning.

Also @ Harvard Health - Diet and depression

Tuesday February 27 2018
A new UK study investigated levels of inappropriate antibiotic prescribing by GPs in England. This was defined as prescribing antibiotics where guidelines say they're of little to no benefit.

Thanks for stopping by.